CBIO Q4 2017 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$337M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0+100.0% YoY

Gross Profit

-$69,565

Operating Income

-$10M

Net Income

-$9M

EPS (Diluted)

$-0.26

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$964,501

Balance Sheet

Total Assets

$129M

Total Liabilities

$9M

Stockholders' Equity

$120M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	-$500	+100.0%
Gross Profit	-$69,565	-$50,791	-37.0%
Operating Income	-$10M	-$8M	-14.1%
Net Income	-$9M	-$8M	-11.2%